JP6604851B2 - 不活性フォーマット - Google Patents
不活性フォーマット Download PDFInfo
- Publication number
- JP6604851B2 JP6604851B2 JP2015552050A JP2015552050A JP6604851B2 JP 6604851 B2 JP6604851 B2 JP 6604851B2 JP 2015552050 A JP2015552050 A JP 2015552050A JP 2015552050 A JP2015552050 A JP 2015552050A JP 6604851 B2 JP6604851 B2 JP 6604851B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protein
- heavy chain
- cells
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 325
- 102000004169 proteins and genes Human genes 0.000 claims description 315
- 210000004027 cell Anatomy 0.000 claims description 185
- 150000001413 amino acids Chemical class 0.000 claims description 152
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 120
- 229920001184 polypeptide Polymers 0.000 claims description 118
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 118
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 89
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 60
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 45
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 30
- 108060003951 Immunoglobulin Proteins 0.000 claims description 26
- 102000018358 immunoglobulin Human genes 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 26
- 230000006052 T cell proliferation Effects 0.000 claims description 25
- 230000002829 reductive effect Effects 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 17
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 17
- 238000002825 functional assay Methods 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 281
- 235000001014 amino acid Nutrition 0.000 description 182
- 229940024606 amino acid Drugs 0.000 description 150
- 238000000034 method Methods 0.000 description 62
- 238000006467 substitution reaction Methods 0.000 description 46
- 239000000427 antigen Substances 0.000 description 43
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 230000035772 mutation Effects 0.000 description 43
- 238000002965 ELISA Methods 0.000 description 37
- 239000002953 phosphate buffered saline Substances 0.000 description 35
- 239000000523 sample Substances 0.000 description 32
- 102000009109 Fc receptors Human genes 0.000 description 27
- 108010087819 Fc receptors Proteins 0.000 description 27
- 238000011534 incubation Methods 0.000 description 27
- 239000012636 effector Substances 0.000 description 26
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 102220259964 rs1554074777 Human genes 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 20
- 229940027941 immunoglobulin g Drugs 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 150000001540 azides Chemical class 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- 230000006044 T cell activation Effects 0.000 description 16
- 125000000539 amino acid group Chemical group 0.000 description 16
- 230000002147 killing effect Effects 0.000 description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 14
- 230000009977 dual effect Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000282567 Macaca fascicularis Species 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108010073807 IgG Receptors Proteins 0.000 description 10
- 102000009490 IgG Receptors Human genes 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- -1 aromatic amino acids Chemical class 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000024203 complement activation Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 235000006408 oxalic acid Nutrition 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000011503 in vivo imaging Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000012450 HuMAb Mouse Methods 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002702 ribosome display Methods 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 239000004475 Arginine Chemical group 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 239000004472 Lysine Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001436793 Meru Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009831 antigen interaction Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001585 disappearance potential spectroscopy Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 102000035025 signaling receptors Human genes 0.000 description 2
- 108091005475 signaling receptors Proteins 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 101150028299 CD69 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000256135 Chironomus thummi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000000579 Epigen Human genes 0.000 description 1
- 108010016906 Epigen Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000263 nonmitogenic effect Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000016314 protein import into mitochondrial matrix Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、Fc領域における3つの修飾から生じる、細胞活性化に至るいかなるFc受容体媒介性機能も誘導しない点で不活性である第1ポリペプチドおよび第2ポリペプチドを含む、抗体などの、タンパク質に関する。
抗体のFc領域によって媒介されるエフェクター機能は、病原体の死滅ならびに抗原のクリアランスおよび分解といった、外来性実体の破壊を可能にする。抗体依存性細胞媒介性細胞傷害作用(ADCC)および抗体依存性細胞媒介性食作用(ADCP)は、Fc受容体(FcR)を保有する細胞にFc領域が結合することによって惹起され、一方、補体依存性細胞傷害作用(CDC)は、補体活性化の古典的経路を惹起するC1qにFc領域が結合することによって惹起される。
[本発明1001]
第1ポリペプチドおよび第2ポリペプチドを含むタンパク質であって、該第1および第2ポリペプチドが各々、少なくとも免疫グロブリン重鎖のヒンジ領域、CH2領域、およびCH3領域を含み、該第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応する位置におけるアミノ酸が、それぞれL、L、およびDではない、タンパク質。
[本発明1002]
前記第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応する位置におけるアミノ酸が、それぞれL、L、およびDではなく、ヒトIgG1重鎖における位置N297およびP331に対応する位置におけるアミノ酸が、それぞれQおよびSではない、本発明1001のタンパク質。
[本発明1003]
前記タンパク質が、わずか10%、例えばわずか8%、わずか7%、わずか5%、わずか3%、わずか1%、およびわずか0%しか野生型タンパク質から逸脱しない血漿クリアランス速度(mL/日/kg)を有し、血漿クリアランス速度が、曲線下面積(AUC)で割った対象へ投与される用量(μg/kg)によって算出され、AUC値が濃度-時間曲線から決定される、本発明1001または1002のいずれかのタンパク質。
[本発明1004]
前記第1および第2ポリペプチドが、それぞれ免疫グロブリンの第1および第2重鎖である、前記本発明のいずれかのタンパク質。
[本発明1005]
前記第1および第2ポリペプチドが、それぞれ第1および第2結合領域をさらに含む、前記本発明のいずれかのタンパク質。
[本発明1006]
前記タンパク質が、免疫グロブリンの第1および第2軽鎖をさらに含み、該第1軽鎖がジスルフィド架橋を介して前記第1重鎖と連結されており、該第2軽鎖がジスルフィド架橋を介して前記第2重鎖と連結されており、それによって、第1結合領域および第2結合領域がそれぞれ形成されている、前記本発明のいずれかのタンパク質。
[本発明1007]
前記第1および第2結合領域のうちの少なくとも1つがCD3に結合する、前記本発明のいずれかのタンパク質。
[本発明1008]
少なくとも前記第1ポリペプチドのヒトIgG1重鎖におけるL234、L235、およびD265に対応する位置におけるアミノ酸が、それぞれL、L、およびDではなく、前記第1結合領域がCD3に結合する、前記本発明のいずれかのタンパク質。
[本発明1009]
前記第1および第2結合領域の両方がCD3に結合する、前記本発明のいずれかのタンパク質。
[本発明1010]
前記タンパク質が、CD3に結合する単一特異性抗体として存在する場合、末梢血単核細胞(PBMC)に基づく機能アッセイにおいてCD69発現を測定した場合に、野生型タンパク質と比較して少なくとも50%、例えば少なくとも60%、少なくとも70%、少なくとも80%、少なくとも90%、少なくとも99%、および100%低下したFc媒介性CD69発現を媒介する、前記本発明のいずれかのタンパク質。
[本発明1011]
前記タンパク質が、CD3に結合する単一特異性抗体として存在する場合、PBMCに基づく機能アッセイにおいてT細胞増殖を測定した場合に、野生型タンパク質と比較して少なくとも50%、例えば少なくとも60%、少なくとも70%、少なくとも80%、少なくとも90%、少なくとも99%、および100%低下したFc媒介性T細胞増殖を媒介する、前記本発明のいずれかのタンパク質。
[本発明1012]
前記第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応する位置におけるアミノ酸が、疎水性アミノ酸または極性アミノ酸である、前記本発明のいずれかのタンパク質。
[本発明1013]
前記第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応する位置におけるアミノ酸が、脂肪族非荷電アミノ酸、芳香族アミノ酸、または酸性アミノ酸である、前記本発明のいずれかのタンパク質。
[本発明1014]
前記第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応するアミノ酸が、それぞれF、E、およびA;またはA、A、およびAである、前記本発明のいずれかのタンパク質。
[本発明1015]
前記第1および第2ポリペプチドのうちの少なくとも1つにおいて、ヒトIgG1重鎖における位置L234、L235、およびD265に対応するアミノ酸が、それぞれF、E、およびAである、前記本発明のいずれかのタンパク質。
[本発明1016]
免疫グロブリン重鎖のアイソタイプが、IgG1、IgG2、IgG3、およびIgG4からなる群より選択される、前記本発明のいずれかのタンパク質。
[本発明1017]
少なくとも前記第1結合領域が、
a.SEQ ID NO:6に示される重鎖可変領域配列およびSEQ ID NO:12に示される軽鎖可変領域配列を含む結合領域;
b.SEQ ID NO:8に示される重鎖可変領域配列およびSEQ ID NO:12に示される軽鎖可変領域配列を含む結合領域;ならびに
c.SEQ ID NO:9に示される重鎖可変領域配列およびSEQ ID NO:10に示される軽鎖可変領域配列を含む結合領域
からなる群より選択される、前記本発明のいずれかのタンパク質。
[本発明1018]
前記第1および第2ポリペプチドの両方が本発明1001〜1016のいずれかに記載されるものである、前記本発明のいずれかのタンパク質。
[本発明1019]
前記第1結合領域が前記第2結合領域とは異なる標的に結合する、前記本発明のいずれかのタンパク質。
[本発明1020]
前記標的が、異なる細胞上に存在する、本発明1019のタンパク質。
[本発明1021]
前記第1ポリペプチドにおいて、ヒトIgG1重鎖におけるT366、L368、K370、D399、F405、Y407、およびK409からなる群より選択される位置に対応する位置におけるアミノ酸のうちの少なくとも1つが置換されており、前記第2ポリペプチドにおいて、ヒトIgG1重鎖におけるT366、L368、K370、D399、F405、Y407、およびK409からなる群より選択される位置に対応する位置におけるアミノ酸のうちの少なくとも1つが置換されており、かつ該第1および該第2ポリペプチドの該置換が同じ位置においてではない、前記本発明のいずれかのタンパク質。
[本発明1022]
ヒトIgG1重鎖におけるF405に対応する位置におけるアミノ酸が、前記第1ポリペプチドにおいてLであり、かつヒトIgG1重鎖におけるK409に対応する位置におけるアミノ酸が、前記第2ポリペプチドにおいてRであるか、またはその逆である、本発明1021のタンパク質。
[本発明1023]
抗体である、前記本発明のいずれかのタンパク質。
[本発明1024]
タンパク質が二重特異性抗体である、本発明1001〜1023のいずれかのタンパク質。
[本発明1025]
前記第1および第2ポリペプチドの両方において、ヒトIgG1重鎖におけるL234、L235、およびD265に対応する位置におけるアミノ酸が、それぞれF、E、およびAであり、かつ前記第1結合領域がCD3に結合し、かつ前記第2結合領域が癌特異的標的に結合する、本発明1024のタンパク質。
[本発明1026]
前記本発明のいずれかに記載される、親タンパク質の変異体。
[本発明1027]
抗体である、本発明1026の変異体。
[本発明1028]
前記本発明のいずれかのタンパク質または変異体を含む、組成物。
[本発明1029]
本発明1001〜1025のいずれかのタンパク質、または本発明1026および1027のいずれかの変異体、ならびに薬学的に許容される担体を含む、薬学的組成物。
[本発明1030]
疾患の治療における使用のための、本発明1001〜1025のいずれかのタンパク質、本発明1026および1027のいずれかの変異体、本発明1028の組成物、または本発明1029の薬学的組成物。
[本発明1031]
本発明1001〜1025のいずれかのタンパク質、本発明1026および1027のいずれかの変異体、本発明1028の組成物、または本発明1029の薬学的組成物を対象へ投与する工程を含む、癌の治療方法。
[本発明1032]
疾患が、癌、感染症、または自己免疫疾患である、本発明1030〜1031のいずれかの使用または方法。
本明細書に記載するように、抗体のFc領域中のアミノ酸位置における特定の修飾が、タンパク質を不活性にする非活性修飾であることがわかった。具体的には、特定の態様が、野生型抗体の血漿クリアランス速度に匹敵するインビボ血漿クリアランス速度を有することが示された。
元のアミノ酸−位置−置換されたアミノ酸;
周知のアミノ酸命名法を参照して、任意のアミノ酸残基を示すためのコードXaaおよびXを含む、三文字コードまたは一文字コードが用いられる。したがって、「L234F」または「Leu234Phe」という表記は、タンパク質が、野生型タンパク質での位置234におけるアミノ酸に対応するタンパク質アミノ酸の位置に、ロイシンのフェニルアラニンによる置換を含むことを意味する。
元のアミノ酸−位置;または例えば「L234」。
「Leu234Phe,Arg,Lys,Trp」または「L234F,R,K,W」または「L234F/R/K/W」または「L234をF, R, KまたはWに」。
a.SEQ ID NO:6で示される重鎖可変領域配列およびSEQ ID NO:12で示される軽鎖可変領域配列を含む結合領域;
b.SEQ ID NO:8で示される重鎖可変領域配列およびSEQ ID NO:12で示される軽鎖可変領域配列を含む結合領域;ならびに
c.SEQ ID NO:9で示される重鎖可変領域配列およびSEQ ID NO:10で示される軽鎖可変領域配列を含む結合領域、
からなる群より選択される。
さらなる局面において、本発明は、ヒトIgG1重鎖におけるL234、L235およびD265に対応する位置におけるアミノ酸が、L、L、およびDではない、本発明に従う第1または第2ポリペプチドをコードする核酸に関する。本発明に従う第1または第2ポリペプチドをコードする核酸が、本明細書に記載の特定のアミノ酸位置においてアミノ酸置換を含むことが、さらに想定される。従って、一態様において、核酸は、SEQ ID NO:20に従う配列を有する第1または第2ポリペプチドをコードする。SEQ ID NO:20で示されるアミノ酸配列において、特定の3つのアミノ酸置換L234F、L235EおよびD265Aはボールドの下線付き文字によって示されている。
a)本明細書上記に記載の本発明のハイブリドーマまたは宿主細胞を培養する工程、および
b)培養培地から本発明の抗体を回収および/または精製する工程。
a)そのようなヌクレオチド配列を含む発現ベクターを含む宿主細胞を培養する工程、および
b)培養培地から抗体融合タンパク質を回収および/または精製する工程。
一局面において、本発明は、本明細書に記載の局面および態様のいずれかに規定されるような、抗体などの、タンパク質、および薬学的に許容される担体を含む、薬学的組成物を提供する。
別の局面において、本発明は、医薬としての使用のための、本明細書に記載の任意の局面または態様に規定されるような本発明のタンパク質、例えば抗体、または薬学的組成物に関する。
本発明の非活性タンパク質はまた、本明細書に記載されるタンパク質を含む組成物を用いて、診断目的で使用され得る。従って、本発明は、本明細書に記載されるタンパク質を用いる診断方法および組成物を提供する。そのような方法および組成物は、純粋な診断目的で、例えば、疾患の検出または同定に、および治療的処置の進展のモニタリング、疾患の進行のモニタリング、処置後の状態の評価、疾患の再発のモニタリング、疾患の発症のリスクの評価等に使用することができる。
− サンプルと本発明のタンパク質とを、タンパク質がサンプル中の標的に結合できる条件下で接触させる工程;および
− 複合体が形成されたかどうかを分析する工程
を含む方法に関する。典型的には、サンプルは、生物学的サンプルである。
− 本発明の標的特異的抗体;および
− キットの使用説明書
を含むキットに関する。
非活性変異
Fc領域中に1つまたは複数のアミノ酸置換を有するいくつかの抗体変異体を作製した。非活性Fc領域は、単球などの血液細胞上に存在するFc受容体と、または古典的補体経路を活性化するためにC1qと、抗体が相互作用することを防ぐ。Fc活性の低下を、Fc領域中のアミノ酸置換の異なる組み合わせを含有する抗体変異体において試験した。変異N297Q、L234A、L235A、L234F、L235E、D265A、およびP331Sを含む、最大で5つのアミノ酸置換を導入した。これらの5つのアミノ酸位置のうちの1つまたは複数における置換をK409RおよびF405L IgG1骨格に導入した。以下のFcドメイン変異体を作製した:NQ(N297Q置換を指す)、LFLE(L234F/L235E置換を指す)、LALA(L234A/L235A置換を指す)、LFLENQ(L234F/L235E/N297Q置換を指す)、LFLEDA(L234F/L235E/D265A置換を指す)、DA(D265A置換を指す)、DAPS(D265A/P331S置換を指す)、DANQ(D265A/N297Q置換を指す)、LFLEPS(L234F/L235E/P331S置換を指す)、およびLFLEDANQPS(L234F/L235E/D265A/N297Q/P331S置換を指す)。
様々なCD3抗体を単一特異性および二重特異性フォーマットで使用した。
実施例のいくつかにおいて、HER2に対する抗体を用いた。このHER2-特異的抗体についてのVHおよびVL配列(VH HER2 169およびVL Her2 160、それぞれ、SEQ ID NO:18および19)は、WO2012143524 [Genmab];およびLabrijn et al., PNAS 2013, 110 : 5145-50に記載されている。
実施例のいくつかにおいて、抗体b12、gp120特異的抗体(Barbas, CF. J Mol Biol. 1993 Apr 5;230(3):812-23.)を陰性対照として使用した。
抗体を、以下のように、上述の非活性変異有りまたは無しで、さらにそれらのFc領域において修飾して、IgG1,κまたはIgG1,λとして発現させた:IgG1-HER2-K409R、IgG1-b12-K409R、IgG1-CD3-F405L。抗体の重鎖および軽鎖の両方をコードするプラスミドDNA混合物を、293fectin(Invitrogen, US)を本質的には製造元による記載の通りに用いて、Freestyle HEK293F細胞(Invitrogen, US)に一過性にトランスフェクトした。
培養上清を0.2μmデッドエンドフィルターに通して濾過し、5mL MabSelect SuReカラム(GE Health Care)にロードして、0.1Mクエン酸ナトリウム-NaOH, pH 3によって溶出させた。溶出液を2M Tris-HCl, pH 9によって直ちに中和し、12.6 mM NaH2PO4、140 mM NaCl, pH 7.4(B. Braun)に対して一晩透析した。あるいは、精製後に、溶出液をHiPrep Desaltingカラムにロードして、抗体を12.6 mM NaH2PO4、140 mM NaCl、pH 7.4 (B.Braun)緩衝液中へ交換した。透析または緩衝液の交換後に、サンプルを0.20μmデッドエンドフィルターに通して滅菌濾過した。純度をSDS-PAGEによって決定し、濃度を280 nmでの吸光度によって測定した。精製抗体を4℃で保存した。
二重特異性抗体は、DuoBody(登録商標)技術プラットフォームにより、即ち、WO 2011/147986号およびLabrijn et al. (Labrijn et al., PNAS 2013, 110: 5145-50; Gramer et al., MAbs 2013, 5 : 962-973)に記載されたような2-MEA誘導性Fabアーム交換により、インビトロで作製した。この方法の基礎となっているのは、特定のアッセイ条件下でヘテロ二量体の形成を促進する補完的なCH3領域の使用である。この方法による二重特異性抗体の生成が可能になるように、CH3領域にある種の変異を保有するIgG1分子を作製した:親IgG1抗体の一方にはF405L変異があり、もう一方の親IgG1抗体にはK409R変異がある。二重特異性抗体を作製するために、これらの2つの親抗体を、各抗体が最終濃度0.5mg/mLとなるように、総体積500μLのTE中にて、25または75 mM 2-メルカプトエチルアミン-HCl(2-MEA)とともに、31℃で5時間インキュベートした。この還元反応は、25 mL PBSで平衡化された、PD-10カラム(GE-healthcare, 製品番号17-0851-01)を用いることによって還元剤2-MEAが除去されると停止した。脱塩前に、2 mL PBS (B.Braun, 製品番号3623140)をサンプルへ添加し、体積を2.5 mLへ調節した。溶出を3.5 mL PBS中で行った。サンプルをAmicon Ultra遠心分離ユニット(30 kD MWCO, Millipore, 製品番号UFC803096)において収集し、8分間3000x gで遠心分離することによって濃縮した。体積をPBSで500μLへ調節し(必要に応じて)、サンプルを0.2μmフィルター(Millex-GV, 製品番号SLGV004SL)で滅菌濾過した。二重特異性産物を2〜8℃で保存した。
CD3陽性Jurkat細胞またはHER2陽性AU565細胞への、精製された抗体変異体IgG1-CD3 (F405L変異を含有する、huCLB-T3/4)、IgG1-HER2 (K409R変異を含有する、HER2-169)、および二重特異性(bs)IgG-CD3 x HER2分子(Fcドメイン中に追加の変異を有する)(実施例1を参照のこと)の結合を、FACS分析によって分析した。細胞(1x10 5細胞/ウェル)を、100μL PBS/0.1% BSA/0.02%アジ化物中の抗体調製物の系列希釈物(Jurkat細胞について4倍希釈で範囲2〜10000 ng/mL、およびAU565細胞について4倍希釈で範囲1〜3000 ng/mL)と共に4℃にて30分間ポリスチレン96-ウェル丸底プレート(Greiner bio-one 650101)中でインキュベートした。
T細胞上のCD69発現をFACS分析によって評価し、Fcドメイン中に変異を有するIgG1-CD3抗体と共にインキュベーションした後のT細胞の初期活性化を測定した(実施例1を参照のこと)。
T細胞の増殖に対するCD3抗体変異体(実施例1に記載)の効果を、Roche Applied Science (Cell Proliferation ELISA, BrdUキット, #11647229001; Roche Applied Science, Mannheim, Germany)製の細胞増殖ELISAキットによって評価し、これを製造業者の指示に従って行った。
AU565(ヒト乳癌)細胞を、10% (vol/vol)熱失活CCS、1.5 g/L炭酸水素ナトリウム(Lonza)、1 mMピルビン酸ナトリウム、4.5 g/Lグルコース(Sigma)、50 IU/mLペニシリン、および50μg/mLストレプトマイシンが補われたRPMI 1640中で培養した。細胞株を5% (vol/vol)CO2加湿インキュベーターにおいて37℃で維持した。AU565細胞をほぼコンフルエンシーまで培養した。細胞をトリプシン処理し、培養培地中に再懸濁し、セルストレーナーを通過させ、単一細胞懸濁液を得た。5x104細胞を96-ウェル培養プレートの各ウェルに播種し、細胞を37℃、5% CO2で少なくとも3時間インキュベートし、プレートへの付着を可能にした。
実施例5において行ったような細胞傷害性アッセイ由来の上清サンプル中に存在するサイトカインを、Pro-inflammatoryキット(MSD, # K15007B-1)を使用して定量化した。
標的細胞へ結合された抗体とC1qとの相互作用は、補体活性化の古典的経路における第1段階である。野生型IgG1はC1qについての相互作用部位を有するので、ELISAによってこれらの非活性IgG1変異体へのC1qの相互作用を評価した。
IIa1.6 FcγRI細胞によって発現される高親和性FcγRIへのIgG1-CD3抗体変異体N297Q、LFLE、LFLEDA、LFLENQ、DANQ、LFLEDANQPSおよびLALAの結合を、FACS分析によって評価した。
この試験におけるマウスは、Central Laboratory Animal Facility(Utrecht, The Netherlands)のバリアユニットに収容し、フィルタートップケージに入れた上で、水および飼料を自由に摂取させた。実験はすべて、Utrecht大学の動物倫理委員会によって承認された。7〜10週齢のC.B-17 SCIDマウス(C.B-17/Icr-Prkdc<Scid>/IcrIcoCrl, Charles-River)に対して、1群当たりマウス3匹を用いて、100μgの野生型抗体(IgG1-CD3、IgG1-HER2、またはbsIgG CD3xHER2)またはそれらの非活性変異体(LALA、LFLEDA、LFLENQ、DANQまたはLFLEDANQPS)を静脈内注射した。抗体投与から10分後、4時間後、1日後、2日後、7日後、14日後および21日後に、伏在静脈から50μLの血液サンプルを収集した。血液をヘパリン含有バイアル中に収集し、10,000 x gで5分間遠心分離した。抗体濃度の決定まで血漿を-20℃で貯蔵した。
ヒトT細胞株JurkatまたはカニクイザルT細胞株HSC-Fへの、FcドメインにLFLEDA変異を有するまたは有さないヒト化CD3(huCD3)抗体および二重特異性(bs)IgG1-huCD3 x HER2分子の精製変異体(実施例1を参照のこと)の結合を、FACS分析によって分析した。非活性変異に加えて、LFLEDA抗体変異体は、実施例1に記載されるようにF405LまたはK409R変異を含む。
T細胞上のCD69発現をFACS分析によって評価し、Fc領域中にLFLEDA変異を有するまたは有さないヒト化CD3(huCD3)抗体変異体とのインキュベーション後のT細胞の初期活性化を測定した。非活性変異に加えて、LFLEDA抗体変異体は、実施例10に記載されるようにF405LまたはK409R変異を含む。
ヒトおよびカニクイザルT細胞の増殖に対するヒト化CD3(huCD3)抗体変異体(実施例1および10に記載)の効果を、Roche Applied Science (Cell Proliferation ELISA, BrdUキット, #11647229001; Roche Applied Science, Mannheim, Germany)製の細胞増殖ELISAキットによって評価し、これを製造業者の指示に従って行った。
AU565(ヒト乳癌)細胞を、10% (vol/vol)熱失活CCS、1.5 g/L炭酸水素ナトリウム(Lonza)、1 mMピルビン酸ナトリウム、4.5 g/Lグルコース(Sigma)、50 IU/mLペニシリン、および50μg/mLストレプトマイシンが補われたRPMI 1640中で培養した。細胞株を5% (vol/vol) CO2加湿インキュベーターにおいて37℃で維持した。AU565細胞をほぼコンフルエンシーまで培養し、その後、細胞をトリプシン処理し、培養培地中に再懸濁し、セルストレーナーを通過させ、単一細胞懸濁液を得た。5x104細胞を96-ウェル培養プレートの各ウェルに播種し、細胞を37℃、5% CO2で少なくとも3時間インキュベートし、プレートへの付着を可能にした。
Claims (21)
- 第1ポリペプチドおよび第2ポリペプチドを含むタンパク質であって、該第1および第2ポリペプチドが各々、少なくともヒトIgG1免疫グロブリン重鎖のヒンジ領域、CH2領域、およびCH3領域を含み、該第1および第2ポリペプチドの両方において、該ヒトIgG1重鎖の位置L234、L235、D265、N297、およびP331におけるアミノ酸が、それぞれF、E、A、N、およびPであり、ここでアミノ酸位置は、EUインデックスナンバリングに従って番号付けされている、タンパク質。
- 前記タンパク質が、10%を超えて野生型タンパク質から逸脱しない血漿クリアランス速度(mL/日/kg)を有し、血漿クリアランス速度が、曲線下面積(AUC)で割った対象へ投与される用量(μg/kg)によって算出され、AUC値が濃度-時間曲線から決定され、
該野生型タンパク質が、第1ポリペプチドおよび第2ポリペプチドの両方において、ヒトIgG1重鎖の位置L234、L235、およびD265におけるアミノ酸が、それぞれL、L、およびDである点を除いて、請求項1に記載のタンパク質と同一である、
請求項1記載のタンパク質。 - 前記第1および第2ポリペプチドが、それぞれ免疫グロブリンの第1および第2重鎖である、請求項1または2記載のタンパク質。
- 前記第1および第2ポリペプチドが、それぞれ第1および第2結合領域をさらに含む、請求項1〜3のいずれか一項記載のタンパク質。
- 前記タンパク質が、免疫グロブリンの第1および第2軽鎖を含み、該第1軽鎖がジスルフィド架橋を介して前記第1重鎖と連結されており、該第2軽鎖がジスルフィド架橋を介して前記第2重鎖と連結されている、請求項3または4記載のタンパク質。
- 前記第1および第2結合領域のうちの少なくとも1つがCD3に結合する、請求項4または5記載のタンパク質。
- 前記第1および第2結合領域の両方がCD3に結合する、請求項4〜6のいずれか一項記載のタンパク質。
- 前記タンパク質が、CD3に結合する単一特異性抗体として存在する場合、末梢血単核細胞(PBMC)に基づく機能アッセイにおいてCD69発現を測定した場合に、野生型タンパク質と比較して少なくとも50%低下したFc媒介性CD69発現を媒介する、請求項1〜7のいずれか一項記載のタンパク質。
- 前記タンパク質が、CD3に結合する単一特異性抗体として存在する場合、PBMCに基づく機能アッセイにおいてT細胞増殖を測定した場合に、野生型タンパク質と比較して少なくとも50%低下したFc媒介性T細胞増殖を媒介する、請求項1〜8のいずれか一項記載のタンパク質。
- a.SEQ ID NO:6に示される重鎖可変領域配列およびSEQ ID NO:12に示される軽鎖可変領域配列を含む結合領域;
b.SEQ ID NO:8に示される重鎖可変領域配列およびSEQ ID NO:12に示される軽鎖可変領域配列を含む結合領域;ならびに
c.SEQ ID NO:9に示される重鎖可変領域配列およびSEQ ID NO:10に示される軽鎖可変領域配列を含む結合領域
からなる群より選択される第1結合領域を含む、請求項4〜9のいずれか一項記載のタンパク質。 - 前記タンパク質が、第1および第2結合領域を含み、該第1結合領域が該第2結合領域とは異なる標的に結合する、請求項4〜6および10のいずれか一項記載のタンパク質。
- 前記標的が、異なる細胞上に存在する、請求項11記載のタンパク質。
- 前記第1結合領域がCD3に結合し、前記第2結合領域が癌特異的標的に結合する、請求項11または12記載のタンパク質。
- 前記第1ポリペプチドにおいて、前記ヒトIgG1重鎖におけるT366、L368、K370、D399、F405、Y407、およびK409からなる群より選択される位置におけるアミノ酸のうちの少なくとも1つが置換されており、前記第2ポリペプチドにおいて、前記ヒトIgG1重鎖におけるT366、L368、K370、D399、F405、Y407、およびK409からなる群より選択される位置におけるアミノ酸のうちの少なくとも1つが置換されており、かつ該第1および該第2ポリペプチドの該置換が同じ位置におけるものではない、請求項1〜13のいずれか一項記載のタンパク質。
- ヒトIgG1重鎖におけるF405におけるアミノ酸が、前記第1ポリペプチドにおいてLであり、かつヒトIgG1重鎖におけるK409におけるアミノ酸が、前記第2ポリペプチドにおいてRであるか、またはその逆である、請求項14記載のタンパク質。
- 抗体である、請求項1〜15のいずれか一項記載のタンパク質。
- タンパク質が二重特異性抗体である、請求項1〜16のいずれか一項記載のタンパク質。
- 請求項1〜17のいずれか一項記載のタンパク質を含む、組成物。
- 請求項1〜17のいずれか一項記載のタンパク質および薬学的に許容される担体を含む、薬学的組成物。
- 疾患の治療における使用のための、請求項1〜17のいずれか一項記載のタンパク質、請求項18記載の組成物、または請求項19記載の薬学的組成物。
- 疾患が、癌、感染症、または自己免疫疾患である、請求項20記載のタンパク質、組成物、または薬学的組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361751045P | 2013-01-10 | 2013-01-10 | |
US61/751,045 | 2013-01-10 | ||
DKPA201300019 | 2013-01-10 | ||
DKPA201300019 | 2013-01-10 | ||
PCT/EP2013/064330 WO2014006217A1 (en) | 2012-07-06 | 2013-07-05 | Dimeric protein with triple mutations |
EPPCT/EP2013/064330 | 2013-07-05 | ||
PCT/EP2014/050340 WO2014108483A1 (en) | 2013-01-10 | 2014-01-09 | Inert format |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016508153A JP2016508153A (ja) | 2016-03-17 |
JP2016508153A5 JP2016508153A5 (ja) | 2017-02-16 |
JP6604851B2 true JP6604851B2 (ja) | 2019-11-13 |
Family
ID=49881390
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015519244A Active JP6514103B2 (ja) | 2012-07-06 | 2013-07-05 | 三重変異を有する二量体タンパク質 |
JP2015552050A Active JP6604851B2 (ja) | 2013-01-10 | 2014-01-09 | 不活性フォーマット |
JP2022075888A Pending JP2022115955A (ja) | 2012-07-06 | 2022-05-02 | 三重変異を有する二量体タンパク質 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015519244A Active JP6514103B2 (ja) | 2012-07-06 | 2013-07-05 | 三重変異を有する二量体タンパク質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022075888A Pending JP2022115955A (ja) | 2012-07-06 | 2022-05-02 | 三重変異を有する二量体タンパク質 |
Country Status (10)
Country | Link |
---|---|
US (4) | US11180572B2 (ja) |
EP (3) | EP2869845B1 (ja) |
JP (3) | JP6514103B2 (ja) |
CN (1) | CN104736174B (ja) |
AU (4) | AU2013285355A1 (ja) |
BR (1) | BR112015000167B1 (ja) |
PL (1) | PL2943507T3 (ja) |
SG (2) | SG11201408646VA (ja) |
SI (1) | SI2943507T1 (ja) |
WO (2) | WO2014006217A1 (ja) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
CA3221018A1 (en) | 2008-01-15 | 2009-07-23 | Ravindra Majeti | Markers of acute myeloid leukemia stem cells |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
CN110066339A (zh) * | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
JP2014518615A (ja) | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
EP3792285A1 (en) | 2013-03-15 | 2021-03-17 | The Board of Trustees of the Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
US20160031985A1 (en) * | 2013-03-15 | 2016-02-04 | Katherine S. Bowdish | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
MX2015014017A (es) | 2013-04-02 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Variante de la region fc. |
PE20151807A1 (es) | 2013-04-29 | 2015-12-02 | Hoffmann La Roche | Anticuerpos modificados de union a fcrn humano y metodo de utilizacion |
SG10201800982QA (en) | 2013-07-05 | 2018-03-28 | Genmab As | Humanized or chimeric cd3 antibodies |
PE20210648A1 (es) | 2013-12-17 | 2021-03-26 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
EP3094649A1 (en) * | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding properties |
RU2727639C2 (ru) * | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
CN105916880B (zh) | 2014-01-15 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
CA2939198A1 (en) | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
CN113416252A (zh) | 2014-05-29 | 2021-09-21 | 宏观基因有限公司 | 三特异性结合分子和其使用方法 |
CA2960797A1 (en) * | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
MX2017005150A (es) * | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a. |
TWI656133B (zh) | 2014-12-19 | 2019-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
AU2016205967B2 (en) * | 2015-01-08 | 2021-11-11 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016164480A1 (en) * | 2015-04-07 | 2016-10-13 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
US20180171017A1 (en) * | 2015-06-05 | 2018-06-21 | Chugai Seiyaku Kabushiki Kaisha | Combined use of immune activators |
CN107849145B (zh) | 2015-06-16 | 2021-10-26 | 基因泰克公司 | 抗cd3抗体及其使用方法 |
EP3322727A1 (en) * | 2015-07-15 | 2018-05-23 | Genmab A/S | Humanized or chimeric cd3 antibodies |
PE20181275A1 (es) | 2015-08-28 | 2018-08-03 | Amunix Operating Inc | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo |
BR112018003186A2 (pt) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anticorpos anti-pd-1 e seus métodos de uso |
EA201890613A1 (ru) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | Полипептиды, связывающие cd3 |
JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
BR112018011058A2 (pt) * | 2015-12-01 | 2018-11-21 | Genmab B.V. | ?anticorpo, composição, método para tratamento de um indivíduo tendo um câncer, kit de partes, e, uso de um anticorpo ou composição? |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017122098A2 (en) * | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
WO2017129737A1 (en) * | 2016-01-27 | 2017-08-03 | Csl Behring Recombinant Facility Ag | Recombinant igg fc multimers |
US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
SG11201808979UA (en) * | 2016-04-15 | 2018-11-29 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
WO2018011421A1 (en) * | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
CA3029744A1 (en) * | 2016-07-22 | 2018-01-25 | Gliknik Inc. | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding |
SG11201900616UA (en) | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
EP3497126A4 (en) * | 2016-08-12 | 2020-04-08 | Janssen Biotech, Inc. | ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF |
IL265109B2 (en) | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized Clostridium toxin preparations without protein |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
JP7277363B2 (ja) | 2016-11-01 | 2023-05-18 | ジェンマブ ビー.ブイ. | ポリペプチド変異体およびその使用 |
KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018145075A1 (en) * | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
MA47449A (fr) * | 2017-02-10 | 2019-12-18 | Genmab Bv | Variants polypeptidiques et ses utilisations |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
JP7330942B2 (ja) * | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー.ブイ. | 二重特異性抗cd37抗体、モノクローナル抗cd37抗体、およびそれらの使用方法 |
EP3609921A2 (en) | 2017-04-13 | 2020-02-19 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
WO2018204363A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
AR111830A1 (es) | 2017-05-25 | 2019-08-21 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
MA49259A (fr) * | 2017-06-07 | 2020-04-15 | Genmab Bv | Anticorps thérapeutiques à base d'hexamères d'igg mutées |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
US11529425B2 (en) * | 2017-09-07 | 2022-12-20 | Dingfu Biotarget Co., Ltd. | Immunoconjugates comprising signal regulatory protein alpha |
EP3684818A2 (en) | 2017-09-21 | 2020-07-29 | UMC Utrecht Holding B.V. | Anti-gd2 antibody for the treatment of neuroblastoma |
US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
PE20211116A1 (es) | 2018-02-08 | 2021-06-23 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso |
CN111971298A (zh) | 2018-03-12 | 2020-11-20 | 健玛保 | 抗体 |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
CN111971090B (zh) * | 2018-03-14 | 2024-02-23 | 阿菲姆德股份有限公司 | 双特异性egfr/cd16抗原结合蛋白 |
KR20200132938A (ko) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법 |
JP2021518411A (ja) * | 2018-03-21 | 2021-08-02 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Fcバリアント組成物およびその使用方法 |
CR20200549A (es) * | 2018-04-13 | 2021-03-18 | Affimed Gmbh | Constructos de fusión de anticuerpos que se acoplan a células nk |
SG11202010601VA (en) * | 2018-05-03 | 2020-11-27 | Genmab Bv | Antibody variant combinations and uses thereof |
WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
MA52951A (fr) * | 2018-06-22 | 2021-04-28 | Genmab Holding B V | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
PE20211858A1 (es) * | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
MA53123A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
WO2020086776A1 (en) * | 2018-10-23 | 2020-04-30 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
AU2020224154A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
JP2022530934A (ja) * | 2019-02-22 | 2022-07-05 | 武▲漢▼友芝友生物制▲薬▼有限公司 | 改変されたFc断片、それを含む抗体、及びそれらの使用 |
GB201910900D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
JP2022545741A (ja) | 2019-08-30 | 2022-10-28 | アジェナス インコーポレイテッド | 抗cd96抗体およびその使用方法 |
EP4028424A1 (en) | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
CN112646041B (zh) * | 2019-10-12 | 2023-11-10 | 上海睿智化学研究有限公司 | 包含抗体ch3域的异源二聚体及含其的抗体、融合蛋白 |
EP4055046A1 (en) * | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
IL293423A (en) | 2019-12-13 | 2022-07-01 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
EP4107179A1 (en) * | 2020-02-19 | 2022-12-28 | adivo GmbH | Modified fc regions |
US20230140384A1 (en) | 2020-03-09 | 2023-05-04 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
EP4121456A1 (en) | 2020-03-18 | 2023-01-25 | Genmab A/S | Antibodies binding to b7h4 |
JP2023523011A (ja) | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス,インコーポレーテッド | T細胞関連のがん細胞に結合する多機能性分子およびその使用 |
GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
KR20230066393A (ko) | 2020-09-10 | 2023-05-15 | 젠맵 에이/에스 | 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
US20230312757A1 (en) | 2020-09-10 | 2023-10-05 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
IL301102A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
EP4221742A1 (en) | 2020-10-02 | 2023-08-09 | Genmab A/S | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
MX2023008302A (es) | 2021-01-13 | 2023-09-25 | Visterra Inc | Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos. |
CA3210971A1 (en) * | 2021-03-12 | 2022-09-15 | Bart-Jan DE KREUK | Non-activating antibody variants |
WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
CN117396509A (zh) | 2021-05-07 | 2024-01-12 | 健玛保 | 包含结合b7h4和cd3的双特异性抗体的药物组合物 |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Antibodies against interleukin 9 and methods of using them |
TW202328192A (zh) | 2021-09-06 | 2023-07-16 | 荷蘭商珍美寶公司 | 能結合cd27之抗體、彼之變異體及彼等之用途 |
TW202330610A (zh) * | 2021-10-08 | 2023-08-01 | 丹麥商珍美寶股份有限公司 | 結合至cd30及cd3之抗體 |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
TW202406571A (zh) | 2022-04-13 | 2024-02-16 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
TW202409090A (zh) | 2022-05-12 | 2024-03-01 | 丹麥商珍美寶股份有限公司 | 在組合療法中能夠結合到cd27之結合劑 |
WO2023242371A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
WO2024048490A1 (ja) * | 2022-08-29 | 2024-03-07 | 第一三共株式会社 | 変異Fc領域を含む抗体薬物コンジュゲート |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU650629B2 (en) | 1989-08-09 | 1994-06-30 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
ES2199216T3 (es) | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
PT651805E (pt) | 1992-07-17 | 2007-02-28 | Dana Farber Cancer Inst Inc | Método de ligação intracelular de moléculas-alvo |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
FR2717187B1 (fr) | 1994-03-10 | 1996-05-31 | Transgene Sa | Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt. |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
JP2000515731A (ja) * | 1996-06-14 | 2000-11-28 | スミスクライン・ビーチャム・コーポレイション | 6量体融合タンパク質およびその使用 |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
WO1999051642A1 (en) | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
KR100887482B1 (ko) | 1999-01-15 | 2009-03-10 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
ES2335775T3 (es) | 1999-04-15 | 2010-04-05 | Crucell Holland B.V. | Produccion de protenia recombinante en una celula humana que comprende al menos una proteina e1 de adenovirus. |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | HER2/neuに対するヒトモノクローナル抗体 |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
CA2448319C (en) | 2001-05-31 | 2010-07-27 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
JP4500044B2 (ja) | 2001-07-04 | 2010-07-14 | クロマジェニックス ビー.ブイ. | 遺伝子転写を調節する特性を含むdna配列及びそのようなdna配列を検出し且つ使用するための方法 |
AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
WO2003107218A1 (ja) | 2002-05-31 | 2003-12-24 | セレスター・レキシコ・サイエンシズ株式会社 | 相互作用予測装置 |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
PT2357006E (pt) | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
NZ541050A (en) | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
EP1762617A1 (en) | 2003-01-07 | 2007-03-14 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
ES2697327T3 (es) | 2003-11-06 | 2019-01-23 | Seattle Genetics Inc | Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador |
CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
AU2004290070A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
EP2154157A3 (en) * | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
EP2357201B1 (en) * | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
EP2213683B1 (en) * | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant Fc regions |
JP4487068B2 (ja) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法 |
EP1817340B1 (en) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
WO2006104989A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
AU2006298519A1 (en) | 2005-05-09 | 2007-04-12 | Glycart Biotechnology Ag | Antigen binding molecules having modified Fc regions and altered binding to Fc receptors |
WO2007005612A2 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
EP1909846B1 (en) | 2005-08-05 | 2018-12-26 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
EP1973950B1 (en) | 2006-01-05 | 2014-09-17 | Genentech, Inc. | Anti-ephb4 antibodies and methods using the same |
EP1994000B1 (en) | 2006-02-02 | 2017-08-23 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
SG170110A1 (en) * | 2006-03-10 | 2011-04-29 | Macrogenics Inc | Identification and engineering of antibodies with variant heavy chains and methods of using same |
JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
US20100184959A1 (en) | 2007-03-19 | 2010-07-22 | Medimmune Limited | Polypeptide Variants |
CA2685675C (en) * | 2007-05-01 | 2016-02-16 | Research Development Foundation | Immunoglobulin fc libraries |
MX2009013816A (es) | 2007-06-21 | 2010-02-24 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos. |
WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
ES2433379T3 (es) | 2007-08-01 | 2013-12-10 | Syntarga B.V. | Análogos de CC-1065 sustituidos y sus conjugados |
US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US8507656B2 (en) * | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
SG10201914027VA (en) | 2008-06-27 | 2020-03-30 | Merus Nv | Antibody producing non-human mammals |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
DE102008039957A1 (de) | 2008-08-27 | 2010-03-04 | Continental Automotive Gmbh | Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
TWI572359B (zh) * | 2008-10-14 | 2017-03-01 | 建南德克公司 | 免疫球蛋白變異體及其用途 |
CN106967062A (zh) | 2008-11-03 | 2017-07-21 | 辛塔佳股份有限公司 | 新型cc‑1065类似物及其缀合物 |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2010132872A1 (en) | 2009-05-15 | 2010-11-18 | Novimmune S.A | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists |
CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
KR101791430B1 (ko) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | 이펙터 기능이 제거된 항체 Fc 돌연변이체 |
EP3778917A3 (en) | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
EP2523976B1 (en) | 2010-01-11 | 2018-04-25 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
EA201201273A1 (ru) | 2010-03-10 | 2013-02-28 | Генмаб А/С | Моноклональные антитела к с-мет |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
CN103153339B (zh) | 2010-05-27 | 2021-05-04 | 根马布股份公司 | 针对her2表位的单克隆抗体 |
NZ604003A (en) | 2010-05-27 | 2015-04-24 | Genmab As | Monoclonal antibodies against her2 |
EP3281956A3 (en) | 2010-06-15 | 2018-04-18 | Genmab A/S | Human antibody drug conjugates against tissue factor |
KR101612999B1 (ko) | 2010-08-24 | 2016-04-15 | 로슈 글리카트 아게 | 활성화가능 이중특이적 항체 |
CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
CN103562224B (zh) | 2011-02-23 | 2017-08-22 | 弗·哈夫曼-拉罗切有限公司 | 针对人il33r的抗体及其用途 |
US20140112926A1 (en) | 2011-03-16 | 2014-04-24 | Amgen Inc. | Fc VARIANTS |
US20140170149A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
SG10201703425RA (en) * | 2011-05-21 | 2017-05-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
SG10201800982QA (en) | 2013-07-05 | 2018-03-28 | Genmab As | Humanized or chimeric cd3 antibodies |
AU2016205967B2 (en) | 2015-01-08 | 2021-11-11 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
EP3322727A1 (en) | 2015-07-15 | 2018-05-23 | Genmab A/S | Humanized or chimeric cd3 antibodies |
PE20211858A1 (es) | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
-
2013
- 2013-07-05 US US14/413,178 patent/US11180572B2/en active Active
- 2013-07-05 AU AU2013285355A patent/AU2013285355A1/en not_active Abandoned
- 2013-07-05 SG SG11201408646VA patent/SG11201408646VA/en unknown
- 2013-07-05 WO PCT/EP2013/064330 patent/WO2014006217A1/en active Application Filing
- 2013-07-05 JP JP2015519244A patent/JP6514103B2/ja active Active
- 2013-07-05 EP EP13735254.8A patent/EP2869845B1/en active Active
- 2013-07-05 BR BR112015000167-0A patent/BR112015000167B1/pt active IP Right Grant
- 2013-07-05 SG SG10201605703TA patent/SG10201605703TA/en unknown
- 2013-07-05 CN CN201380045878.0A patent/CN104736174B/zh active Active
-
2014
- 2014-01-09 EP EP14700200.0A patent/EP2943507B1/en active Active
- 2014-01-09 PL PL14700200T patent/PL2943507T3/pl unknown
- 2014-01-09 WO PCT/EP2014/050340 patent/WO2014108483A1/en active Application Filing
- 2014-01-09 US US14/760,157 patent/US10590206B2/en active Active
- 2014-01-09 JP JP2015552050A patent/JP6604851B2/ja active Active
- 2014-01-09 EP EP20159405.8A patent/EP3738979A1/en active Pending
- 2014-01-09 SI SI201431575T patent/SI2943507T1/sl unknown
-
2018
- 2018-05-17 AU AU2018203510A patent/AU2018203510A1/en not_active Abandoned
-
2020
- 2020-02-06 US US16/783,720 patent/US11485796B2/en active Active
- 2020-04-07 AU AU2020202410A patent/AU2020202410A1/en not_active Abandoned
-
2022
- 2022-05-02 JP JP2022075888A patent/JP2022115955A/ja active Pending
- 2022-09-22 US US17/950,350 patent/US20230322947A1/en active Pending
- 2022-10-27 AU AU2022259785A patent/AU2022259785A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104736174A (zh) | 2015-06-24 |
AU2018203510A1 (en) | 2018-06-07 |
US20150337049A1 (en) | 2015-11-26 |
SI2943507T1 (sl) | 2020-07-31 |
US11180572B2 (en) | 2021-11-23 |
BR112015000167B1 (pt) | 2021-11-23 |
WO2014006217A1 (en) | 2014-01-09 |
SG11201408646VA (en) | 2015-01-29 |
JP2015524387A (ja) | 2015-08-24 |
US20230322947A1 (en) | 2023-10-12 |
EP2869845B1 (en) | 2019-08-28 |
EP2943507A1 (en) | 2015-11-18 |
US20150175707A1 (en) | 2015-06-25 |
SG10201605703TA (en) | 2016-09-29 |
WO2014108483A1 (en) | 2014-07-17 |
PL2943507T3 (pl) | 2020-07-27 |
EP3738979A1 (en) | 2020-11-18 |
CN104736174B (zh) | 2019-06-14 |
EP2869845A1 (en) | 2015-05-13 |
JP2016508153A (ja) | 2016-03-17 |
JP2022115955A (ja) | 2022-08-09 |
JP6514103B2 (ja) | 2019-05-15 |
AU2022259785A1 (en) | 2022-12-01 |
US20200332022A1 (en) | 2020-10-22 |
BR112015000167A2 (pt) | 2017-08-08 |
EP2943507B1 (en) | 2020-02-26 |
WO2014006217A9 (en) | 2015-02-26 |
AU2013285355A1 (en) | 2015-01-29 |
US11485796B2 (en) | 2022-11-01 |
US10590206B2 (en) | 2020-03-17 |
AU2020202410A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11485796B2 (en) | Inert format | |
JP7104000B2 (ja) | ヒト化またはキメラcd3抗体 | |
US11359015B2 (en) | Humanized or chimeric CD3 antibodies | |
ES2792199T3 (es) | Formato inerte | |
JP2024512386A (ja) | 非活性化抗体バリアント | |
BR112015032986B1 (pt) | Anticorpo, microrganismo, composição, métodos para produzir um anticorpo e in vitro para detectar a presença de antígeno de cd3 ou uma célula que expressa cd3 em uma amostra, e, kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170110 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180926 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190912 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191015 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6604851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |